Trial Profile
Changes of Cerebral Spinal Fluid APPSα Levels Under Oral Therapy With Acitretin 30 mg Daily in Patients With Mild to Moderate Alzheimer's Disease: a Multicenter Prospective Randomised Placebo-controlled Parallel-group Study. [Veränderungen der APPSα -Konzentration in der Zerebrospinalflüssigkeit nach der oralen Therapie mit 30 mg Acitretin täglich bei Patienten mit leichter bis mittelschwerer Alzheimer-Krankheit: multizentrische prospektive randomisierte placebo-kontrollierte Studie mit Parallelgruppen-Design.]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Acitretin (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms ADAM
- 15 May 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 21 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2009-011881-27).
- 20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.